Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +75

MiniMed adds Abbott dual glucose-ketone sensor to portfolio, posts Q4 sales beat

AI-generated analysis

🤝 MiniMed expanded its existing partnership with Abbott to include the integration of dual glucose-ketone sensors into its product portfolio.

📊 The company reported fourth-quarter sales of $837 million, which exceeded Wall Street consensus estimates of $788.7 million.

💸 Despite the revenue beat, MiniMed posted a net loss of $183 million, or 68 cents per share, for the quarter ended April 24, 2026.

📈 International sales grew by 22.4% to reach $599 million, driven largely by the expansion of the Simplera CGM system.

🇺🇸 U.S. sales increased modestly by 1.5% to $238 million as customers wait for FDA clearance on the new MiniMed Flex system.

⚠️ The Abbott Libre Duo dual sensors are currently CE marked in Europe but remain investigational and not yet cleared for use in the U.S.

🩸 The new sensors will continuously measure both glucose and ketone levels every minute to help prevent diabetic ketoacidosis emergencies.

🤖 CEO Que Dallara stated that integrating these sensors adds an additional layer of intelligence and protection to MiniMed's smart dosing systems.

🚀 For fiscal 2027, MiniMed projects organic revenue growth of approximately 10% with an adjusted EBITDA margin of around 16%.

💉 The company is developing a Fit patch pump designed to challenge the current market leader, Insulet's Omnipod 5.

🧠 A next-generation algorithm called Vivera is in a U.S. pivotal study and is expected to receive FDA clearance next year.

🏭 Manufacturing operations for the Fit pump are underway with initial capacity planned to serve 20,000 patients at launch.

📅 Both the Fit patch pump and Vivera algorithm are on track for FDA clearance in the coming year according to CEO Dallara.

🔍 BTIG analysts maintained a "Buy" rating for MiniMed following the strong earnings results and upcoming product launches.

🌍 Analysts view fiscal 2027 as a catalyst-rich year due to the Flex launch, continued Go expansion, and sensor rollouts outside the U.S.

Bullish Signals
  • MiniMed posted fourth-quarter sales of $837 million, which beat the consensus forecast of $788.7 million by approximately $48.3 million.
  • Shares of MiniMed (Nasdaq:MMED) rose 5.82% to $13.02 following the announcement of the Abbott partnership and strong earnings.
  • International sales grew 22.4% to $599 million, driven by the expansion of the Simplera CGM system.
  • The company expects organic revenue growth of approximately 10% for fiscal 2027 with an adjusted EBITDA margin of around 16%.
  • MiniMed is launching its new MiniMed Flex system this month and has already begun taking pre-orders for the device.
  • The Fit patch pump manufacturing operations are underway with initial capacity to serve 20,000 patients at launch.
  • Analysts from BTIG maintained a 'Buy' rating on MiniMed, labeling fiscal 2027 as a 'catalyst-rich year' for the company.
  • The next-generation Vivera algorithm is progressing well in its pivotal trial, currently at around 50% of targeted enrollment.
Risk Factors
  • MiniMed reported a significant bottom-line slide of 8.9% despite a 15.6% increase in sales, resulting in losses of $183 million for the quarter ended April 24, 2026.
  • U.S. sales growth was modest at only 1.5%, driven by customers waiting for the upcoming launch of the MiniMed Flex system rather than current product demand.
  • The Abbott Libre Duo and Libre Duo 10 Day sensors remain investigational in the U.S., limiting immediate commercialization potential despite CE mark approval in Europe.
Full Analysis
MiniMed expanded its strategic partnership with Abbott to integrate the company's dual glucose-ketone sensors into its portfolio, following a prior collaboration that included the Instinct sensor. The new integration involves commercializing Abbott's Libre Duo and Libre Duo 10 Day sensors, which continuously measure both glucose and ketone levels to provide real-time visibility and help minimize the risk of diabetic ketoacidosis (DKA). While these sensors have received CE mark approval in Europe, they remain investigational in the U.S. MiniMed plans to offer them across its automated insulin delivery and smart multiple daily injection systems, with further updates on regulatory milestones expected in coming months. In conjunction with this partnership announcement, MiniMed reported fourth-quarter earnings that exceeded Wall Street consensus sales forecasts. The company recorded revenue of $837 million for the three months ended April 24, 2026, representing a 15.6% increase despite an 8.9% bottom-line slide due to losses of $183 million. International sales drove significant growth at $599 million (up 22.4%), largely fueled by the Simplera CGM expansion, while U.S. sales grew modestly by 1.5% as customers awaited the upcoming launch of the MiniMed Flex system. For fiscal 2027, MiniMed projects organic revenue growth of approximately 10% and an adjusted EBITDA margin of around 16%. Looking ahead, CEO Que Dallara highlighted a complete portfolio transformation aimed at offering patients every option across their diabetes journey within 18 months. Key upcoming developments include the Fit patch pump, which is set to challenge competitors like Insulet's Omnipod 5, and Vivera, its third-generation algorithm for automated insulin delivery currently in a pivotal U.S. study. Both products are on track for FDA clearance next year, with manufacturing operations already underway for the Fit pump to serve an initial capacity of 20,000 patients. Analysts from BTIG maintained a "Buy" rating, citing fiscal 2027 as a catalyst-rich year driven by the Flex launch, continued MiniMed Go expansion, and broader sensor rollouts outside the U.S.